5-IAI Stats & Data

• Identity uncertainty is a major risk: multiple forum analyses from 2010–2013 allege that products sold as “5‑IAI” were often inactive or different stimulants; treat all samples as unknown until reagent‑tested and, where available, lab drug checking confirms identity. This directly affects dose, onset, and safety planning.

• Mechanistically, 5‑IAI behaves as a serotonin>norepinephrine≈dopamine releasing agent and substituted for MDMA in rodent discrimination studies, implying entactogenic effects with stimulant load; human data remain anecdotal.

• Animal work found markedly less serotonergic neurotoxicity than para‑iodoamphetamine at comparable high doses, yet small decreases in serotonergic markers occurred; avoid high/repeated dosing.

• A modern review notes affinity at 5‑HT2B among other 5‑HT receptors; while functional agonism is not fully characterized, conservative spacing is advised (valvulopathy is a theoretical risk across 5‑HT2B‑active entactogens).

• Expect typical releaser risks: hyperthermia, tachycardia, and hyponatremia with overhydration or MDMA‑style water‑loading; use small, regular sips (~250 ml/hour in heat) and avoid alcohol‑induced dehydration. (General HR extrapolated to serotonergic releasers.)

• Bruxism, muscle tension, and insomnia are common; magnesium may help bruxism for some but evidence is mixed; non‑drug measures (jaw rests, gum, warm compress) are lower‑risk first‑line.

• Redosing yields diminishing returns and disproportionate side effects; plan a single dose, avoid stacking, and do not chase effects with stimulants. (Pattern observed across community reports.)

• Space sessions generously (≥4–6 weeks) to allow serotonergic recovery and reduce mood after‑effects; shorter intervals correlate with more severe comedowns across releasers. (Best‑practice HR extrapolation.)

• If on any serotonergic prescription (SSRI/SNRI/MAOI/triptan), avoid entirely due to elevated serotonin syndrome risk highlighted in HR lists and combo charts.

• Non‑selective beta‑blockers during acute stimulation may worsen vasoconstriction; if chest pain, severe headache, hyperthermia, or confusion occur, seek emergency care rather than self‑medicating.

• Prefer oral titration over insufflation/rectal to reduce local harm and dose overshoot; nasal use commonly reports irritation without clear benefit.

• Because formal human PK is lacking, treat timing and interactions as uncertain; build extra buffers before driving, sleeping, or combining with any other psychoactives.